Weight Loss Stack: The Complete Stack Guide

At a Glance

Overview

The Basics

The Weight Loss Stack covers the main peptide lanes that now shape obesity treatment and body-composition discussion. Some members act as anchor therapies with enough efficacy to move total body weight in a clinically meaningful way. Others are narrower satiety, visceral-fat, or experimental metabolic tools.

semaglutide, tirzepatide, and retatrutide are the anchor therapies. cagrilintide is the satiety-adjunct lane because it broadens appetite control through amylin biology rather than another incretin-only mechanism. tesamorelin is the body-composition specialist focused on visceral fat. aod-9604 and 5-amino-1mq are the experimental tail of the stack, where the rationale becomes more mechanistic and the evidence becomes thinner.

Seeing three GLP-1-family anchors on one page is a comparison aid, not a recommendation to run them together. The operative question is which anchor belongs in the conversation, not how many anchors can be layered.

That is the structure of the current field: high-efficacy anchors, one meaningful satiety adjunct lane, a narrower visceral-fat lane, and a set of lower-confidence metabolic adjuncts.

The Science

This stack spans four levels of anti-obesity strategy. First are the obesity anchors: GLP-1 monoagonism (semaglutide), dual GIP/GLP-1 agonism (tirzepatide), and triple glucagon/GIP/GLP-1 agonism (retatrutide). Second is the amylin lane (cagrilintide), which is pharmacologically complementary rather than a simple duplicate of GLP-1 biology. Third is the body-composition lane (tesamorelin), which has stronger evidence for central adiposity and liver-fat effects than for broad standalone obesity pharmacotherapy. Fourth are lower-confidence metabolic adjuncts (aod-9604, 5-amino-1mq).

The stack logic is therefore hierarchical, not additive. It is not scientifically coherent to treat every member as an equal candidate for simultaneous use. The strongest editorial and safety position is to treat the anchor drugs as alternatives, not as a baseline polypharmacy cluster.

How It Works / Synergy Analysis

The Basics

The best way to think about this stack is to separate anchor choice from adjunct choice.

Anchor choice is the high-leverage decision. semaglutide, tirzepatide, and retatrutide all influence the same broad obesity-control system, but they do it with escalating complexity. Semaglutide is the mature one-pathway option. Tirzepatide adds a second pathway. Retatrutide adds a third and has the highest upside, but also the most uncertainty because it is still investigational.

Adjunct choice is different. cagrilintide adds amylin signaling, which is why it has a real combination identity with semaglutide in CagriSema. tesamorelin adds a visceral-fat and trunk-composition angle. aod-9604 and 5-amino-1mq sit further out in the experimental-metabolic territory.

The Science

semaglutide, tirzepatide, and retatrutide all include GLP-1-family biology, but they are not interchangeable in mechanism depth. semaglutide is GLP-1 only. tirzepatide adds GIP, which helps explain its stronger average weight-loss efficacy and better body-composition ratios relative to semaglutide in non-diabetic obesity. retatrutide adds partial glucagon receptor agonism, giving it a direct hepatic fat-oxidation and energy-expenditure lane that neither semaglutide nor tirzepatide fully share.

cagrilintide is what changes the stack from a list of competing incretins into something with real combo nuance. It is an amylin analogue, not another GLP-1-family anchor. That distinction matters because CagriSema has been studied formally, while there is no similar evidence base for running semaglutide with tirzepatide, semaglutide with retatrutide, or tirzepatide with retatrutide.

This leads to the core rule for the stack:

• choose one anchor;
• understand whether cagrilintide belongs as an adjunct;
• treat everything else as more niche or experimental.

Key Benefits & Goals

The Basics

The stack covers two broad decisions. First is anchor selection: semaglutide, tirzepatide, or retatrutide. Second is whether there is a reason to think about a satiety adjunct, a visceral-fat specialist, or a more speculative metabolic tool.

That separation matters because appetite control, visceral-fat reduction, and experimental metabolic support are often discussed as though they belong to the same category of effect. They do not.

The Science

The strongest benefits in this collection are:

• large obesity-trial weight-loss efficacy from semaglutide, tirzepatide, and especially retatrutide;
• meaningful glycemic and cardiometabolic improvement from the approved anchors;
• structured satiety-combo logic from cagrilintide with semaglutide;
• visceral-fat and liver-fat targeting from tesamorelin.

The lower-confidence benefits are:

• lipolysis support from aod-9604;
• metabolic signaling support from 5-amino-1mq.

The stack is therefore strongest when it is used to triage goals and evidence tiers, not when it is treated like a shopping list.

Evidence Summary

The Basics

The stack now has a clear top tier. retatrutide, tirzepatide, and semaglutide are the real obesity anchors. cagrilintide sits just below that because its role is more adjunctive, even though the evidence for it is real and clinically meaningful. tesamorelin is credible but more specialized. aod-9604 and 5-amino-1mq remain the thin-evidence members.

This hierarchy reflects where the field currently is. retatrutide and cagrilintide are much closer to the obesity-treatment frontier than many simplified peptide lists suggest.

The Science

Evidence calibration across this stack:

• Strong approved-anchor evidence: semaglutide, tirzepatide
• Strong investigational-anchor evidence: retatrutide
• Moderate-to-strong adjunct evidence: cagrilintide
• Moderate niche evidence: tesamorelin
• Thin to exploratory evidence: aod-9604, 5-amino-1mq

This means the collection can now discuss both current clinical standards and the next likely wave of obesity agents without pretending they all occupy the same role.

Component Highlights

Quick links: Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Tesamorelin, AOD-9604, 5-Amino-1MQ.

Semaglutide

Semaglutide remains the mature anchor, with the broadest clinical use, the strongest cardiovascular-outcomes credibility, and the longest real-world track record in this stack. It is best treated as the conservative approved anchor rather than as a compound that should run beside tirzepatide or retatrutide.

Tirzepatide

Tirzepatide is the approved high-output anchor. It generally outperforms semaglutide on average weight-loss magnitude and body-composition profile in non-diabetic obesity, which makes it the practical "performance" benchmark inside the approved group.

Retatrutide

Retatrutide is the investigational frontier anchor. Its triple agonism gives it the strongest average efficacy in this stack. The cost of that upside is uncertainty: it is not yet FDA approved, and it should be treated as an alternative anchor, not something to run on top of semaglutide or tirzepatide.

Cagrilintide

Cagrilintide is the amylin-adjunct lane. It matters because it broadens satiety signaling without simply duplicating another GLP-1-family anchor. This is why CagriSema exists and why cagrilintide belongs in the stack.

Tesamorelin

Tesamorelin is the visceral-fat specialist. It is a more targeted body-composition tool than a mainstream obesity anchor, but it remains relevant when abdominal adiposity and trunk composition matter more than scale weight alone.

AOD-9604

AOD-9604 is still the low-drama experimental adjunct: good safety story, modest expected effect, and a role more aligned with stubborn-fat optimization than primary obesity treatment.

5-Amino-1MQ

5-Amino-1MQ remains the most speculative member in the stack. It is interesting because of the NNMT/NAD+ story, but it still belongs in the "curious experimental adjunct" tier rather than the first-line obesity lane.

Comparative Analysis

The Basics

The shortest possible interpretation of the stack is:

• semaglutide = established approved anchor
• tirzepatide = stronger approved anchor
• retatrutide = strongest investigational anchor
• cagrilintide = satiety adjunct with real combo relevance
• tesamorelin = visceral-fat specialist
• aod-9604 = low-risk low-ceiling optimizer
• 5-amino-1mq = experimental metabolic wild card

This framing is more useful than treating every member as an equal candidate for the same role.

The Science

The cleanest comparison framework is:

• For strongest approved obesity efficacy: tirzepatide
• For strongest evidence maturity and cardiovascular reassurance: semaglutide
• For highest investigational efficacy: retatrutide
• For structured combo satiety logic: cagrilintide
• For visceral-fat/body-composition refinement: tesamorelin
• For subtle adjunctive fat-metabolism support: aod-9604
• For exploratory adipocyte-metabolism theory: 5-amino-1mq

This is also where the stack now handles an important safety distinction: competing anchors should be compared, not casually combined.

Getting Started

The Basics

The clearest way to approach this stack is to separate anchor selection from adjunct selection.

Semaglutide, tirzepatide, and retatrutide define the anchor lane. Cagrilintide sits in the satiety-adjunct lane. Tesamorelin, AOD-9604, and 5-Amino-1MQ sit further out as body-composition or experimental metabolic adjuncts. That lane-based framing keeps the collection comparative rather than protocol-like.

The Science

An evidence-first reading order for this collection is:

1. compare semaglutide, tirzepatide, and retatrutide;
2. understand cagrilintide as an amylin-pathway adjunct rather than another competing GLP-1-family anchor;
3. use tesamorelin when the phenotype is more about visceral-fat distribution or trunk composition;
4. reserve aod-9604 and 5-amino-1mq for exploratory, lower-confidence contexts.

That structure reduces the risk of readers turning the collection into a protocol that was never actually studied.

General Dosing Considerations

The Basics

This stack is not suitable as a dosing template, because the members span:

• approved weekly incretin anchors,
• an investigational triple agonist,
• an amylin analogue,
• a daily GHRH analogue,
• and experimental metabolic adjuncts.

That is not one protocol language. It is several different protocol languages sharing one page.

The Science

Dosing decisions need to remain at the individual-guide level because the stack contains overlapping incretin biology plus distinct adjunct lanes. Consult your healthcare provider for specific dosing guidance. At the collection level, the main job is lane selection and evidence calibration, not schedule design.

What to Expect

The Basics

With anchors like semaglutide, tirzepatide, or retatrutide, appetite effects and early tolerance signals usually come first. cagrilintide belongs in the stronger-satiety, higher-GI-burden conversation, especially in combo contexts. Tesamorelin, AOD-9604, and 5-Amino-1MQ are more likely to produce narrower body-composition changes or less certain effects than dramatic short-term scale changes.

The Science

Rough response windows across the collection:

• Weeks 1-4: appetite and GI-tolerance signals from anchor incretins; early satiety intensification with cagrilintide
• Weeks 4-8: more visible weight-loss momentum from anchors; first meaningful body-composition shifts for some tesamorelin users
• Weeks 8-12+: clearer divergence between high-efficacy anchors and subtle adjuncts
• Months 6-12: where the best obesity-trial anchor data becomes most representative

The important nuance is that not all "weight-loss stack" members create the same signal. Appetite suppression, visceral-fat redistribution, and low-level metabolic support are not interchangeable outcomes.

Safety & Interactions

The Basics

The most common misreading of this stack is that multiple GLP-1-family anchors belong together in one protocol. The safest answer is usually no. semaglutide, tirzepatide, and retatrutide should be treated as alternative anchors unless a formal protocol says otherwise. The fact that they all belong in the obesity conversation does not mean they belong in the same syringe case.

cagrilintide is different because it is not just another GLP-1-family anchor. It is the member that makes the combo conversation legitimate at all. But even there, the model is a studied combination like CagriSema, not improvising multiple overlapping incretin drugs.

The Science

The strongest labeling and evidence-based cautions in this stack are:

• Official Wegovy prescribing information says semaglutide should not be coadministered with other semaglutide-containing products or other GLP-1 receptor agonists.
• Official Zepbound prescribing information says coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended.
• retatrutide lacks approval labeling, but because it already contains GLP-1, GIP, and glucagon agonism, there is no good evidence basis for presenting it as something to run in parallel with semaglutide or tirzepatide.
• cagrilintide has a real semaglutide combo identity through CagriSema, but that is not a general license for multi-anchor stacking.

The remaining adjuncts bring their own risks:

• tesamorelin: edema, IGF-1 elevation, glucose monitoring, injection-site reactions
• aod-9604: modest efficacy but lower overall burden
• 5-amino-1mq: uncertain long-term human safety, sleep disruption, and inconsistent results

The cleanest editorial rule is:

• one obesity anchor at a time;
• treat cagrilintide as the only meaningful combo-adjacent satiety lane here;
• keep the niche and experimental members in clearly bounded roles.

Frequently Asked Questions

Is this a real seven-compound protocol?

No. This is a navigation stack, not a validated all-at-once regimen. Its purpose is to compare obesity anchors, satiety adjuncts, and more experimental metabolic tools.

Should semaglutide and tirzepatide be used together?

Usually no. Official labeling already pushes against coadministration with other GLP-1 receptor agonists. In this stack they are better treated as alternative anchors.

What about retatrutide with semaglutide or tirzepatide?

That should also be treated as an alternative-anchor question, not a typical parallel-use strategy. Retatrutide already contains GLP-1-family activity plus additional receptor activity, and there is no good clinical evidence basis for framing it as a casual add-on to the approved anchors.

Why is cagrilintide different?

Because it adds amylin signaling rather than just duplicating another GLP-1-family anchor. That is why CagriSema exists as a studied combo and why cagrilintide belongs in this stack.

Why was orforglipron not added?

Because its own guide explicitly states that it is a non-peptide small molecule GLP-1 agonist. It is relevant to the obesity conversation, but not to this peptide stack definition.

Which member has the strongest weight-loss upside right now?

Among the current KB set, retatrutide has the strongest investigational upside, tirzepatide is the strongest approved anchor by average efficacy, and semaglutide remains the most mature approved reference point.

Related Guides

Quick links: Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Tesamorelin, AOD-9604, 5-Amino-1MQ, Orforglipron, MOTS-C, NAD+, Tesofensine.

Members of This Collection

• Semaglutide
• Tirzepatide
• Retatrutide
• Cagrilintide
• Tesamorelin
• AOD-9604
• 5-Amino-1MQ

Complementary Guides

• Orforglipron
• MOTS-C
• NAD+
• Tesofensine

Related Collections in This KB

• Anti-Inflammation Stack
• Mitochondrial Optimization Stack
• Longevity Stack